Emily and Chris Campbell Announce “Not These Ovaries, Inc.” A 501(c)(3) Non-Profit Organization To Accelerate The Cure For Ovarian Cancer

Miami. FL — Emily and Chris Campbell announce the launch of “Not These Ovaries, Inc.” (NTO), a 501(c)(3) non-profit organization that will help accelerate funds for ovarian cancer clinical trials and support frontline researchers.

Their goal is simple. They don’t want anyone in the future to go through the hardship and anxiety they went through two years ago when Emily was diagnosed with ovarian cancer.

“We were on our own to find a cure,” explains 35-year-old Emily Campbell, who is now cancer-free. “We knew from the beginning that this disease needed more research and definitive answers. It was a guessing game for us from the start.”

Ovarian cancer presents unique challenges, including the struggle to find accurate information and appropriate medical care. Many patients face conflicting advice, outdated resources, and long waits for specialist appointments.

The rarity of certain ovarian cancer types — such as borderline ovarian tumors (BOT) and low-grade serous (LGSOC), which serve as particular areas of focus for NTO — often means that even experienced physicians may lack familiarity with the latest diagnostic techniques and treatment options. This information gap can lead to delays in diagnosis, misdiagnosis, or suboptimal treatment plans, underscoring the critical need for improved education, research, and support networks in the field of ovarian cancer care.

Adds 38-year-old Chris Campbell, Emily’s husband and advocate: “We had to spend weeks sifting through convoluted medical websites, fighting for timely appointments, navigating antiquated processes, battling medical gaslighting, and even hand-delivering medical specimens to secure second opinions in time to finally get the right diagnosis. It was a torturous time.”

The Campbells believe that “Action Saves Lives.” They also believe that the more information that is shared, the better the results.

According to research:

1 in 10 people diagnosed with ovarian cancer is under 45.
There are two rarer, less understood types that often affect this demographic: borderline and low-grade serous. But there’s very little research and funding into these — donations can change that.
The average survival rate for low-grade serous ovarian cancer is 9 years.

It’s notoriously hard to detect and even harder to treat — mainly because there hasn’t been enough research.

There are currently NO proven FDA approved drug treatments.
Besides a surgery developed decades ago that often involves removing the entire reproductive system (resulting in early-stage menopause and fertility loss), there are no tests to detect ovarian cancer, no FDA-approved drug treatments to manage it, and no vaccines to prevent it. There’s hardly any research about borderline and low-grade serous ovarian cancer at all. Not These Ovaries is working to change that.

The Campbells feel that their experience in recent years raising investment capital for a leading B2B marketing software and technology company taught them the skills they needed to help fund the most promising ovarian cancer research work.

Most recently, Emily and Chris partnered with Dana-Farber Cancer Institute, raising $1.8 million for one of the largest low-grade ovarian cancer projects in the U.S. Following that experience, the Campbells founded NTO with the goal of raising $100 million to better the lives of tens of thousands of women impacted by this disease each year.

Emily and Chris are available to answer any questions donors may have. Visit https://www.nottheseovaries.org/ to make a connection.

The NTO website also contains information about the studies and trials the Campbells are helping fund, with more added every week.

Disclaimer: This information is for educational purposes only and not a substitute for professional medical advice. Not These Ovaries, Inc. is not a medical provider. Always consult your physician for medical concerns.

Press Contact:

Lois Whitman-Hess
HWH PR
(917) 822-2591
loisw@hwhpr.com